Trial results

Impact GLP-1 Agonists Following Bariatric

NCT06132477 on ClinicalTrials.gov · last registry update 2026-01-22

An unusually large phase 4: 150 participants, more than double the 72 typical for the stage. Due to report July 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Effect of GLP1-RA on weight loss. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 1 February 2024 — 2 years so far. semaglutide is approved in the US, but not for diabetes and hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P4

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

University of Missouri-Columbia

Sponsor type

Other

Enrollment

150

Started

2024-02-01

Primary completion

2028-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Effect of GLP1-RA on weight loss

Conditions studied

Morbid Obesity · Metabolic Syndrome · Diabetes Mellitus · Hypertension · Obstructive Sleep Apnea of Adult

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.